Abiopharma

New Form DEFM14A - ESSA Pharma Inc. Filed: 2025-08-11 AccNo: 0001104659-25-075843 Size: 10 MB

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

New Form 15-12G - Third Harmonic Bio, Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177392 Size: 11 KB

New Form 8-K - Cosmos Health Inc. Filed: 2025-08-11 AccNo: 0001477932-25-005628 Size: 528 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: …

New Form 6-K - Nyxoah SA Filed: 2025-08-11 AccNo: 0001104659-25-075831 Size: 104 KB

New Form EFFECT - DiaMedica Therapeutics Inc. Filed: 2025-08-08 AccNo: 9999999995-25-002540 Size: 1 KB

New Form 6-K - BELITE BIO, INC Filed: 2025-08-11 AccNo: 0001104659-25-075837 Size: 109 KB

New Form EFFECT - Longeveron Inc. Filed: 2025-08-08 AccNo: 9999999995-25-002544 Size: 1 KB

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion